The interindividual genetic variations in drug metabolizing enzymes and transporters
influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision …

Individual variability in drug efficacy and drug safety is a major challenge in current clinical
practice, drug development, and drug regulation. For more than 5 decades, studies of …

Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused
by very low or absent plasma clearance of LDL, substantially raised LDL cholesterol, and …

Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of
occlusive vascular events in a wide range of individuals. We aimed to assess the safety and …

Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of
occlusive vascular events in a wide range of individuals. We aimed to assess the safety and …

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with
skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild …

Background Lowering of LDL cholesterol reduces major vascular events, but whether more
intensive therapy safely produces extra benefi ts is uncertain. We aimed to establish effi cacy …

Introduction: Statin-induced myopathy is an important cause of statin intolerance and the
most common cause of statin discontinuation. Observational studies estimate that 10–15 …

Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death
among men and women in the United States1 and worldwide. 2 In 1992, for example …

Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …